Medical devices
MRI enhancer company nabs $30 million
MRI tech company NVision Imaging, based in Germany, scored $30 million in funding in a Series A round, the company announced Thursday. It also earned $19.5 million from the German government. NVision develops metabolic agents injected into patients who undergo MRIs, enabling more sensitive, in-depth images to diagnose and analyze cancer. Rather than simply scanning images for a tumor, for example, doctors might be able to find cancerous tissue based on how it interacts with sugar.
"That allows you more sensitivity, so even if the morphology looks normal, the metabolism is different," Sella Brosh, CEO of NVision, told STAT's Lizzy Lawrence.
Brosh plans to use the funding to build and deploy its system, which involves the injectable agent as well as a machine that amplifies its magnetic signal. It's partnering with Siemens Healthineers to install its system in 50 cancer centers by 2025. "We've been a heavily focused R&D company," Brosh said. "This has been in the works for more than 6 years. It's all about getting getting the systems in the hands of the strongest cancer centers in the world."
Data Privacy
FTC dings genetic testing company over data policies
The Federal Trade Commission has reached a proposed settlement with genetic testing company 1Health.io over allegations it stored genetic data and health records in publicly accessible AWS cloud storage and deceived consumers about the privacy of their data and their ability to delete it. The company, which is also known as Vitagene, sold DNA test kits that offered consumers information about ancestry and wellness.
As part of the settlement, the company will have to pay a $75,000 fine, which the FTC will use for consumer refunds. 1Health.io will also be required to abide by standard data privacy and security practices, like obtaining informed consent for sharing data with third parties, and to conduct biennial data security assessments from a third-party assessor for 20 years.